Eli Lilly has made a foray into the radiopharmaceuticals category with an agreement to buy POINT Biopharma for around $1.4 billion. If the $12.50-per-share all-cash deal is completed, it will give ...

Gordon Scott has been an active investor and technical analyst or 20+ years. He is a Chartered Market Technician (CMT). Michael Logan is an experienced writer, producer, and editorial leader. As a ...

Troy Segal is an editor and writer. She has 20+ years of experience covering personal finance, wealth management, and business news. Andy Smith is a Certified Financial Planner (CFP®), licensed ...